These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22412867)

  • 1. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
    Pantazis N; Morrison C; Amornkul PN; Lewden C; Salata RA; Minga A; Chipato T; Jaffe H; Lakhi S; Karita E; Porter K; Meyer L; Touloumi G;
    PLoS One; 2012; 7(3):e32369. PubMed ID: 22412867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival.
    Staehelin C; Rickenbach M; Low N; Egger M; Ledergerber B; Hirschel B; D'Acremont V; Battegay M; Wagels T; Bernasconi E; Kopp C; Furrer H;
    AIDS; 2003 Oct; 17(15):2237-44. PubMed ID: 14523281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care-a comparison of migrant groups in the German ClinSurv HIV Cohort Study, 1999-2013.
    Zeitlmann N; Gunsenheimer-Bartmeyer B; Santos-Hövener C; Kollan C; An der Heiden M;
    BMC Infect Dis; 2016 Dec; 16(1):739. PubMed ID: 27927190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients?
    Anglaret X; Diagbouga S; Mortier E; Meda N; Vergé-Valette V; Sylla-Koko F; Cousens S; Laruche G; Ledru E; Bonard D; Dabis F; Van de Perre P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(4):361-7. PubMed ID: 9111479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
    Gabillard D; Lewden C; Ndoye I; Moh R; Segeral O; Tonwe-Gold B; Etard JF; Pagnaroat M; Fournier-Nicolle I; Eholié S; Konate I; Minga A; Mpoudi-Ngole E; Koulla-Shiro S; Zannou DM; Anglaret X; Laurent C;
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):555-61. PubMed ID: 23274931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.
    Touloumi G; Pantazis N; Pillay D; Paraskevis D; Chaix ML; Bucher HC; Kücherer C; Zangerle R; Kran AM; Porter K;
    Clin Infect Dis; 2013 Mar; 56(6):888-97. PubMed ID: 23223594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.
    Siedner MJ; Ng CK; Bassett IV; Katz IT; Bangsberg DR; Tsai AC
    Clin Infect Dis; 2015 Apr; 60(7):1120-7. PubMed ID: 25516189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.
    Nash D; Wu Y; Elul B; Hoos D; El Sadr W;
    AIDS; 2011 Jul; 25(12):1523-33. PubMed ID: 21750418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
    Wolbers M; Babiker A; Sabin C; Young J; Dorrucci M; Chêne G; Mussini C; Porter K; Bucher HC;
    PLoS Med; 2010 Feb; 7(2):e1000239. PubMed ID: 20186270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.
    Anglaret X; Minga A; Gabillard D; Ouassa T; Messou E; Morris B; Traore M; Coulibaly A; Freedberg KA; Lewden C; Ménan H; Abo Y; Dakoury-Dogbo N; Toure S; Seyler C;
    Clin Infect Dis; 2012 Mar; 54(5):714-23. PubMed ID: 22173233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
    Lawn SD; Myer L; Bekker LG; Wood R
    BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.
    Lodi S; Phillips A; Touloumi G; Geskus R; Meyer L; Thiébaut R; Pantazis N; Amo JD; Johnson AM; Babiker A; Porter K;
    Clin Infect Dis; 2011 Oct; 53(8):817-25. PubMed ID: 21921225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade.
    Wolday D; Kebede Y; Legesse D; Siraj DS; McBride JA; Kirsch MJ; Striker R
    PLoS One; 2020; 15(5):e0233049. PubMed ID: 32442166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population-based survey data.
    Glaubius R; Kothegal N; Birhanu S; Jonnalagadda S; Mahiane SG; Johnson LF; Brown T; Stover J; Mangal TD; Pantazis N; Eaton JW
    J Int AIDS Soc; 2021 Sep; 24 Suppl 5(Suppl 5):e25784. PubMed ID: 34546644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore.
    Ng OT; Lin L; Laeyendecker O; Quinn TC; Sun YJ; Lee CC; Leo YS
    PLoS One; 2011 Jan; 6(1):e15738. PubMed ID: 21298051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)].
    Caro-Murillo AM; Gutiérrez F; Manuel Ramos J; Sobrino P; Miró JM; López-Cortés LF; Tural C; Moreno A; de Los Santos I; Murillas J; Camino X; Salavert M; Rubio R; Moreno S; del Amo J;
    Enferm Infecc Microbiol Clin; 2009; 27(7):380-8. PubMed ID: 19427080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Bwire R; Nagelkerke NJ; Borgdorff MW
    Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.